Nabriva Therapeutics PLC expected to post a loss of 35 cents a share - Earnings Preview

Nabriva Therapeutics

04/08/2021 24:40

* Nabriva Therapeutics PLC  NBRV.OQ   NBRV.O  is expected
to show a rise in quarterly revenue when it reports results on
August 5. 
* The Dublin, Ireland; Republic of-based company is expected to
report   a 1,129.1% increase in revenue to $5.986 million from
$487 thousand a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Nabriva Therapeutics
PLC is for a loss of 35 cents per share. For the same quarter
last year, the company reported a loss of $1.40 per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $3.68​, about 66.8% above​ its last closing
price of $1.22. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.67       -0.67      -0.53     Beat    20.9
 Dec. 31 2020              -0.95      -1.11     Missed  -16.8
 Sep. 30 2020  -0.90       -0.97      -0.90     Beat    7.7​
 Jun. 30 2020  -1.61       -1.60      -1.40     Beat    12.5
 Mar.          -2.69​      -2.64      -2.50     Beat    5.3​
 31​ 2020​                                              
 Dec. 31 2019  -3.24       -3.32      -2.90     Beat    12.7​
 Sep. 30 2019  -2.82       -2.82      -2.40     Beat    15
 Jun. 30 2019  -3.33       -3.35      -3.00     Beat    10.4
 This summary was machine generated August 3 at 23:40 GMT.  All
figures in US dollars unless otherwise stated